The use of SGLT2 inhibitors in patients with kidney disease is becoming the standard of care. This table covers many of the common potential side effects from several of the major clinical trials. Red- difference showing more adverse in SGLT2i arm, Yellow- borderline difference showing more adverse in SGLT2i arm, White- no difference, Green- more adverse events in placebo arm.
EMPA-REG
CANVAS
CREDENCE
DECLARE-TIMI
DAPA-HF
DAPA-CKD
Comment or reach out with corrections or additions.
Dr. Nasim Wiegley @NWiegley
Assistant Professor
University of California, Davis
